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What was known before: 1 
Anti-VEGF agents are in widespread use as adjuncts to vitreoretinal surgery for advanced 2 
proliferative retinopathy. Detailed data on surgical outcomes is limited to small uncontrolled 3 
studies, although there is now good quality evidence that prior injection of bevacizumab reduces 4 
post-operative vitreous cavity haemorrhage. Ranibizumab has been reported to reduce intra-5 
operative haemorrhage. 6 
 7 
 8 
What this study adds: 9 
This pilot randomised clinical trial investigated ranibizumab pre-treatment before diabetic 10 
vitrectomy-delamination surgery. The study shows that the likely effect size of ranibizumab on 11 
final visual acuity is likely to be small, and with the heterogeneity of outcomes in this condition, a 12 
further definite study powered to detect a significant difference is unlikely to be feasible given the 13 
subject numbers required. Clinicians will likely therefore continue to use anti-VEGF agents in this 14 
condition based on individual experience and preference. 15 
  16 
  17 
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ABSTRACT 65 
Purpose 66 
Our aim was to evaluate the impact of intravitreal ranibizumab pre-treatment on the outcome 67 
of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to 68 
determine the feasibility of a subsequent definitive trial and estimate the effect size and 69 
variability of the outcome measure. 70 
Methods 71 
We performed a pilot randomised double-masked single-centre clinical trial in 30 participants 72 
with tractional retinal detachment associated with proliferative diabetic retinopathy. Seven 73 
days prior to vitrectomy surgery, participants were randomly allocated to receive either 74 
intravitreal ranibizumab (Lucentis®, Novartis Pharmaceuticals UK Ltd.) or subconjunctival 75 
saline (control). The primary outcome was best-corrected visual acuity 12 weeks following 76 
surgery. 77 
Results 78 
At 12 weeks the mean (SD) visual acuity was 46.7 (25) ETDRS letters in the control group 79 
and 52.6 (21) letters in the ranibizumab group. Mean visual acuity improved by 14 (31) 80 
letters in the control group and by 24 (27) letters in the ranibizumab group. We found no 81 
difference in the progression of tractional retinal detachment prior to surgery, the duration of 82 
surgery or its technical difficulty. Vitreous cavity haemorrhage persisted at 12 weeks in 2 of 83 
the control group but none of the ranibizumab group. 84 
Conclusions 85 
Ranibizumab pre-treatment may improve the outcome of vitrectomy surgery for advanced 86 
proliferative diabetic retinopathy by reducing the extent of postoperative vitreous cavity 87 
haemorrhage. However, the effect size appears to be modest; we calculate that a definitive 88 
study to establish a minimally important difference of 5.9 letters at a significance level of 89 
P<0.05 would require 348 subjects in each arm. 90 
  91 
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INTRODUCTION 92 
Advanced proliferative retinopathy is characterized by fibrovascular proliferation, vitreous 93 
haemorrhage and tractional retinal detachment (Figure 1A and B). This condition is 94 
conventionally managed by vitreoretinal surgery, the outcome of which can be limited by 95 
recurrent postoperative vitreous cavity haemorrhage.1, 2 The intraocular administration of 96 
therapeutic anti-vascular endothelial growth factor (VEGF) antibodies is variably used as an 97 
adjunct to vitrectomy with the aim of improving the outcome by facilitating safe delamination 98 
of fibrovascular membranes and reducing the incidence of post-operative vitreous cavity 99 
haemorrhage.3-8 However the value of adjunctive administration of antiVEGF antibodies has 100 
yet to be established with confidence. 101 
Intravitreal ranibizumab pre-treatment, 7 days prior to vitrectomy surgery for diabetic 102 
tractional retinal detachment, can reduce intraoperative haemorrhage.9 The aim of the 103 
present study was to evaluate its impact on postoperative outcomes. The objective was to 104 
measure the effect on visual acuity and ascertain the number of participants that would be 105 
needed to determine such an effect with confidence. 106 
 107 
MATERIALS AND METHODS 108 
We performed a randomised double-masked parallel group pilot study at Moorfields Eye 109 
Hospital (NCT01306981). The study conformed to the Declaration of Helsinki and was 110 
approved prospectively by the Central London Research Ethics Committee 1 of the UK 111 
National Research Ethics Service. All participants gave their informed consent to participate 112 
in the research prior to enrolment.  113 
We included 30 eyes of 30 adult participants having vitrectomy and delamination surgery for 114 
advanced proliferative diabetic retinopathy with fibrovascular complexes and/or tractional 115 
retinal detachment. Eyes with persistent vitreous haemorrhage could be included because of 116 
the use of ultrasonography to evaluate attachment of the retina. We excluded eyes having 117 
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planned combined cataract and vitrectomy, those with only a single focal point of 118 
vitreoretinal attachment apparent on clinical examination or ultrasonography, and those with 119 
cataract or uncontrolled glaucoma. We excluded individuals with visual acuity in the 120 
contralateral eye of 3/60 or poorer, hypersensitivity to the active substance or excipients, 121 
and cerebrovascular, cardiovascular or peripheral vascular disease. 122 
 123 
Seven days (±1 day) prior to vitrectomy surgery, participants were randomly allocated 1:1 to 124 
receive either intravitreal ranibizumab (Lucentis®, 0.5 mg in 0.05 ml solution for injection, 125 
Novartis Pharmaceuticals UK Ltd., Frimley, United Kingdom), or subconjunctival saline 126 
control (sodium chloride, 0.05ml of 0.9% solution for injection) using a 1ml syringe and 30-127 
gauge needle. Randomisation was performed using random permuted blocks of varying 128 
sizes. The allocation sequence was held by the trial statistician and concealed from the 129 
investigator enrolling and assessing participants. An unmasked investigator administered the 130 
study agents. Participants in both groups were prepared identically using topical anaesthetic 131 
and povidone iodine; topical levofloxacin was administered immediately prior to the injection 132 
and 4 times daily for 4 days. The participants, operating surgeons and assessing 133 
investigators were masked to treatment allocation. Participants were assessed at baseline, 134 
immediately prior to surgery, and at 6 weeks and 12 weeks following surgery. 135 
 136 
Experienced vitreoretinal surgeons performed 20-gauge pars plana vitrectomy and en-bloc 137 
delamination of fibrovascular membranes, panretinal endo-photocoagulation, with retinopexy 138 
and endotamponnade if indicated. We recorded the duration of surgery, the number of back-139 
flush cannula and endodiathermy applications required to control haemorrhage, retinal 140 
breaks, intraoperative bleeding score (0-none; 1-mild, stopped by bottle elevation; 2-141 
moderate, forming clots or persistent; 3-severe, covering half of posterior pole) and the 142 
anticipated surgical complexity score (Castellarin et al.).10 143 
 144 
To investigate the impact of ranibizumab on the extent of tractional retinal detachment prior 145 
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to surgery we examined the study eye prior to administration of the study agent and one 146 
week later on the day of surgery by slit-lamp biomicroscopy and ultrasonography (Acuson 147 
Sequoia 512 scanner, 14 MHz linear probe; Siemens Medical Solutions USA; Mountain 148 
View, CA, USA). To investigate the impact on retinal neovascularisation and ischaemia we 149 
performed fluorescein angiography (unless precluded by vitreous haemorrhage); masked 150 
assessors at Moorfields Reading Centre measured the greatest linear dimension and area of 151 
the foveal avascular zone, and the grade of perifoveal capillary non-perfusion. 152 
 153 
The primary outcome measure was Early Treatment Diabetic Retinopathy Study (ETDRS) 154 
best-corrected visual acuity 12 weeks following surgery. Secondary outcome measures 155 
included the extent of tractional retinal detachment and macular perfusion at the time of 156 
surgery; the technical ease of vitrectomy surgery including duration, instrument usage and 157 
intra-operative haemorrhage; and the presence of post-operative vitreous cavity 158 
haemorrhage. This was graded using a previously described scale from 0 – 3 (0 – no 159 
haemorrhage, clear view; 1 – minor haemorrhage with fundus details visible; 2 – moderate 160 
haemorrhage with only disc and major vessels visible; 3 – severe haemorrhage with fundus 161 
details not visible). 11 162 
 163 
For this pilot trial we performed no formal sample size calculation but estimated that 30 164 
subjects would be sufficient to explore the feasibility of a subsequent definitive trial and to 165 
enable calculation of its sample size. The Trial Steering Group approved a statistical 166 
analysis plan prior to analysis of data. We compared baseline characteristics of the 167 
participants allocated to the 2 treatment arms. Normality was assessed by inspection of 168 
histograms. We calculated summary statistics using STATA statistical software (version 12, 169 
StataCorp LP, College Station, TX, USA).  170 
 171 
  172 
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RESULTS 173 
We included 30 eyes of 30 participants and randomly allocated 15 eyes to each arm of the 174 
study, and none were lost to follow-up. All eyes had been managed for proliferative 175 
retinopathy by panretinal photocoagulation prior to enrolment. The participants in the 2 arms 176 
were similar (Table 1) though the overall complexity score derived from ultrasound 177 
assessment of tractional detachment was slightly higher in the ranibizumab group (Table 2).  178 
 179 
At 12 weeks following surgery the mean (standard deviation) visual acuity was 46.7 (25) 180 
ETDRS letters in the control group and 52.6 (21) letters in the ranibizumab group (Figure 2). 181 
The mean visual acuity improved by 14 (31) letters in the control group and by 24 (27) letters 182 
in the ranibizumab group. 183 
 184 
One participant in each group developed new tractional retinal detachment following the 185 
study injection; in neither instance did this involve the macula (Table 2). The mean height of 186 
TRD increased slightly in control eyes following the study injection. No other change in TRD 187 
dimension exceeded the limit of resolution (±1.6 mm) and the overall ultrasound-derived 188 
complexity score was unchanged in both groups. 189 
 190 
The median duration of surgery was greater in the ranibizumab group (63 minutes) than the 191 
control group (51 minutes) (Table 3; P=0.53); intraoperative haemorrhage scores were 192 
similar as were the number of endodiathermy and back-flush cannula applications. The 193 
median surgeon-defined complexity score based on retinal features present at the start of 194 
surgery was slightly higher for the ranibizumab group but the median overall subjective 195 
surgical difficulty score was lower and there were fewer iatrogenic retinal breaks. 196 
 197 
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Any residual vitreous cavity haemorrhage following vitrectomy surgery resolved 198 
progressively in both groups. At six weeks after surgery two of fifteen subjects in the control 199 
group, and one of thirteen subjects in the ranibizumab group who had not received silicone 200 
oil had visible vitreous cavity haemorrhage. While this was moderate in the ranibizumab 201 
group, in the control group both had a severe grade of haemorrhage. Moderate or severe 202 
residual haemorrhage persisted in 2 eyes of the control group at 12 weeks following surgery, 203 
but had fully resolved in the subject in the ranibizumab group. 204 
 205 
At baseline, fluorescein angiograms were gradable in only a minority of participants (3 of the 206 
control group and 5 of the ranibizumab group) owing to media opacity and/or distortion of 207 
foveal anatomy in the majority. All gradable angiograms demonstrated moderate to severe 208 
perifoveal capillary non-perfusion. At 12 weeks, the mean (SD) foveal avascular zone 209 
greatest linear dimension was 637 (236) µm in the control group (n=9) and 765 (576) µm in 210 
the ranibizumab group (n=10); the foveal avascular zone area was 0.315 (0.147) mm2 in the 211 
control group and 0.403 (0.562) mm2 in the ranibizumab group. The median total score for 212 
perifoveal capillary non-perfusion was 14 in both groups, indicating scores of 3-4 (moderate 213 
to severe) in each of the four quadrants.  214 
Ocular and non-ocular adverse events were in keeping with previously published trials of 215 
anti-VEGF agents. The most common adverse event was upper respiratory tract infection 216 
which occurred more commonly in the control group. There were no arterial thrombo-embolic 217 
events or cases of endophthalmitis. There was one serious adverse event in each group. 218 
One participant in the control group was admitted to hospital for management of 219 
hypoglycaemia 10 weeks after surgery, and one participant in the ranibizumab group was 220 
admitted for management of raised intraocular pressure following vitrectomy surgery, an 221 
event judged unlikely to be related to study drug administration. Vitreous cavity haemorrhage 222 
was more frequent in the control group than in the ranibizumab group. 223 
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 DISCUSSION 224 
The results of this trial confirm significant improvement in mean visual acuity 12 weeks 225 
following vitreoretinal surgery for advanced proliferative retinopathy, with or without 226 
ranibizumab pre-treatment, consistent with previous reports. 1 Our findings also suggest a 227 
modest additional benefit of intravitreal injection of ranibizumab one week prior to surgery, 228 
with higher mean visual acuity and greater mean improvement in visual acuity at 12 weeks. 229 
The difference in acuity in this pilot study is not statistically significant.  On the basis of these 230 
data, we calculate that 348 subjects in each group (696 in total) would be required to 231 
determine a clinically relevant treatment difference of 5.9 letters with 90% power and 5% 232 
significance, allowing for 5% loss to follow-up. 233 
Our findings of reduced postoperative vitreous cavity haemorrhage associated with 234 
ranibizumab pre-treatment in vitrectomy surgery are consistent with a previous report that 235 
this also reduces intraoperative haemorrhage during surgery. 9 Earlier studies have shown 236 
conflicting results regarding the utility of bevacizumab in preventing recurrent haemorrhage, 237 
for example Romano et al. found that although pre-operative injection could reduce the 238 
number of recurrent haemorrhages, 12 giving the drug as an intra-operative adjunct did not 239 
prevent post-operative vitreous cavity haemorrhage. 11 Data from the 2015 update to the 240 
Cochrane review of bevacizumab for the prevention of post-operative vitreous cavity 241 
haemorrhage suggest that treatment results in 130 fewer people per 1000 experiencing early 242 
post-operative haemorrhage, although there is considerable heterogeneity of methodology in 243 
the trials included in this systematic review. 8  244 
We found that ranibizumab pre-treatment was associated with a lower intraoperative 245 
bleeding score, greater reduction in retinal neovascularisation and lower prevalence of 246 
persistent vitreous cavity haemorrhage. However,  in contrast to previous studies and a 247 
meta-analysis of these studies that have reported shorter surgical duration or fewer 248 
instrument exchanges following anti-VEGF prior to surgery for proliferative diabetic 249 
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retinopathy,4, 7 we found that the median surgical complexity score was no lower, the mean 250 
duration of vitrectomy was no shorter, and the use of the backflush cannula and 251 
endodiathermy were similar. 252 
Previous studies have highlighted concerns about the development or progression of 253 
tractional retinal detachment associated with progressive fibrosis following intravitreal 254 
administration of anti-VEGF agents, especially in the absence of prior panretinal 255 
photocoagulation.13, 14 Despite the presence of dense media opacity in many, we were able 256 
to determine the impact of ranibizumab pre-treatment on the extent of tractional retinal 257 
detachment prior to surgery in all participants by the use of ultrasonography. In our study, in 258 
which all subjects had been managed previously by panretinal photocoagulation, we 259 
identified no effect of ranibizumab injection on extension of retinal detachment after 7 days. 260 
We chose this interval between injection and surgery to maximise the possibility of benefit 261 
while minimising the risk of harm, and this finding from ultrasound evaluation suggests that 262 
administering ranibizumab in the setting of previously treated proliferative retinopathy may 263 
be safe in this regard.  264 
We identified significant macular ischemia in the participants in both groups but found no 265 
evidence of an impact of intervention in either. Although we conclude that its safety profile 266 
appears to be favourable, the number of subjects in whom angiography was feasible is 267 
insufficient to draw firm conclusions about the impact of ranibizumab injection on the extent 268 
of macular ischemia in this context.  269 
The strengths of our study are that it was randomised and double-masked with a sham 270 
control arm. Since the study included multiple surgeons, all of whom were experienced in 271 
vitrectomy surgery for advanced diabetic retinopathy, the findings are broadly generalisable. 272 
The ability to draw firm conclusions is limited by the small number of subjects included and 273 
the inherent heterogeneity of the condition, in particular the variability of management of 274 
proliferative retinopathy prior to enrolment in the study and difficulty in controlling for variable 275 
11 
 
amounts of prior panretinal photocoagulation. However, the results provide a valuable 276 
indication of the substantial size of the trial that would be needed to confirm with confidence 277 
the impact of ranibizumab pre-treatment in vitrectomy surgery for advanced diabetic 278 
retinopathy. 279 
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 FIGURE LEGENDS 332 
Figure 1A and B – Colour fundus photograph (A) and ultrasound image (B) to show 333 
advanced proliferative diabetic retinopathy. The fundus image shows evidence of 334 
fibrovascular proliferation, pre-retinal haemorrhage and tractional retinal detachment 335 
involving the macula, while the ultrasound shows partial posterior vitreous detachment with 336 
vitreous attachment to tractional retinal detachment. Calliper placement shows measurement 337 
of height and longitudinal base dimension of tractional detachment. 338 
 339 
Figure 2 – Box plots to show visual acuity (VA) by treatment group, shown as mean ± 340 
standard deviation Early Treatment Diabetic Retinopathy Study letter score  341 
 342 
 343 
Table 1. Participants in a pilot randomised study of ranibizumab pre-treatment in diabetic 
vitrectomy 
 
 Control Ranibizumab 
Total number of participants 15 15 
Female gender (number of participants) 9 (60%) 3 (20%) 
Age (years); mean (SD) 48.7 (18) 57.1 (14) 
Ethnicity: (number of participants) 
White or white British 
Black or black British 
Asian or Asian British 
Other 
Not recorded 
 
8 (53%) 
2 (13%) 
2 (13%) 
3 (20%) 
0 
 
8 (53%) 
2 (13%) 
3 (20%) 
1 (7%) 
1 (7%) 
Type of diabetes 
Type 1 (number of participants) 
Type 2 (number of participants)  
 
6 (40%) 
9 (60%) 
 
4 (27%) 
11 (73%) 
Duration of diabetes (years); median (IQR) 21 (15, 28) 19 (10, 23) 
Systolic blood pressure (mmHg) 132 (22) 128 (22) 
Diastolic blood pressure (mmHg) 75 (9) 78 (11) 
HbA1C (glycosylated haemoglobin, %) 9.3 (1.8) (n=13) 8.2 (1.1) (n=14)
Ocular characteristics   
ETDRS letter score 32.3 (19)  28.5 (27)  
RAPD present (number) 3 (20%) 4 (27%) 
Rubeosis present (number) 0 0 
Anterior chamber inflammation grade (0-4) 0 0 
Intraocular pressure (mmHg) 16.5 (4) 16.8 (3) 
Lens status 
Pseudophakic 
Cataract grade 0 
1 
2 
3 
4 
 
3 (20.0%) 
4 (26.7%) 
6 (40.0%) 
1 (6.7%) 
1 (6.7%) 
0  
 
5 (33.3%) 
4 (26.7%) 
5 (33.3%) 
1 (6.7%) 
0  
0  
Vitreous haemorrhage score  
0 (no haemorrhage) 
1 (minor haemorrhage) 
2 (moderate haemorrhage - disc and large vessels 
visible) 
3 (severe haemorrhage - no fundus view) 
 
3 (20.0%) 
8 (53.3%) 
2 (13.3%) 
 
2 (13.3%) 
 
6 (40.0%) 
5 (33.3%) 
1 (6.7%) 
 
3 (20.0%) 
 
Data shown as mean (SD) for normally distributed variables. ETDRS - Early Treatment 
Diabetic Retinopathy Study; RAPD - relative afferent pupillary defect. 
Table 2. Tractional retinal detachment characteristics following study injection in a 
randomised trial of ranibizumab prior to diabetic vitrectomy. 
 
 Control Ranibizumab 
Time-point Baseline 1 week  Baseline  1 week  
TRD characteristics from 
ultrasound 
    
Number of eyes with TRD 6 (40%) 7 (47%) 10 (67%) 11 (73%)
Number of eyes with macula TRD 
involving  
5 (83%) 5 (71%) 5 (50%) 5 (45%) 
Dimensions of TRD (mean (SD)) 
      Height (mm) 
      Base (mm) 
 
2.2(0.5) 
11.9(5.0) x 
13.2(4.6)  
 
2.5(0.6) 
12.6(5.3) x 
13.5(4.4) 
 
2.4(0.9) 
11.9(4.7) x 
11.5(5.3) 
 
2.4(1.0) 
12.1(5.0) x 
12.5 (6.2) 
Ultrasound-derived complexity 
score (0-8; median) 
 
4 
 
4 
 
5 
 
5 
TRD characteristics from colour 
imaging (baseline only) 
    
Number with gradable images 9 - 8 - 
Absent 
Hammock 
Diffuse Central 
Tabletop 
1 
3 
3 
2 
 4 
3 
0 
1 
 
 
TRD - tractional retinal detachment; RRD - rhegmatogenous retinal detachment. 
Table 3. Intraoperative parameters in a trial of ranibizumab in diabetic vitrectomy 
 
 Control Ranibizumab  
Surgeon-determined complexity score  
0 (simple) - 8 (highly complex) (median score) 
4 5  
Duration of vitrectomy (mins)  
median (interquartile range) 
51 (38-82) 63 (42-87) P=0.53, 
Wilcoxon 
Rank-Sum test 
Intraoperative bleeding score (median score) 
0 (none) - 3 (severe) 
2 2  
Endodiathermy applications (mean) 1.5 1.1  
Backflush cannula applications (mean) 2.8 2.5  
Number of iatrogenic retinal breaks (total) 15 12  
Tamponnade agent (number of participants) 
None 
Sulphur hexafluoride 
Perfluoropropane 
Silicone oil 
 
3 (20%) 
11 (73%) 
1 (7%) 
0 (0%) 
 
3 (20%) 
9 (60%) 
1 (7%) 
2 (13%) 
 
Overall surgical difficulty score (median score) 
Scale 0 (simple) - 4 (very difficult) 
3 2  
 
 



